Welcome to our dedicated page for Definium Therapeutics news (Ticker: DFTX), a resource for investors and traders seeking the latest updates and insights on Definium Therapeutics stock.
Definium Therapeutics, Inc. develops investigational therapeutics for psychiatric and neurological disorders. The company’s news centers on DT120 ODT (lysergide tartrate), its lead Phase 3 program for generalized anxiety disorder and major depressive disorder, along with clinical-trial progress, pre-commercial planning, and updates on the treatment landscape for mood and anxiety disorders.
Recurring announcements also include quarterly and annual financial results, investor and analyst events, research publications related to generalized anxiety disorder, and public-company compensation actions such as Nasdaq inducement grants for new employees.
Definium Therapeutics (NASDAQ:DFTX) launched Rerouting Minds, an educational campaign to increase understanding of pharmaceutical lysergide (LSD) and the role of rigorous psychedelic research in mental health care. The campaign targets healthcare providers, psychiatrists, therapists, advocates, and policymakers and provides scientific context on LSD’s medical history (dating to 1938), hypothesized brain effects, and community resources. The release cites that nearly 1 in 4 adults (about 59.3 million in the U.S.) live with a mental health disorder and that over 28 million do not receive treatment. Materials and resources are available at www.definiumtx.com/rerouting-minds.
Definium Therapeutics (Nasdaq: DFTX) said its common shares will begin trading on Nasdaq under the new ticker DFTX effective at market open on January 15, 2026. The company previously expected the change on January 13, 2026 and updated the effective date to January 15. Shareholders do not need to take any action for the ticker symbol change.
Definium Therapeutics (NASDAQ:DFTX) announced a rebrand from MindMed and outlined a late-stage psychiatry program led by DT120 orally disintegrating tablet (ODT). The company expects three Phase 3 topline readouts in 2026: Voyage (1st GAD study) in 2Q, Panorama (2nd GAD study) in 2H, and Emerge (1st MDD study) mid-year. DT120 ODT holds FDA Breakthrough Therapy Designation for GAD. Definium plans FDA submissions for GAD and MDD markets, is preparing commercialization readiness, and continues early‑stage work, including dosing the first patient in a Phase 2a DT4023 study for ASD. The Nasdaq ticker changes to DFTX effective January 13, 2026, and the company will webcast a J.P. Morgan Healthcare Conference presentation on January 14, 2026.